Next Science Limited (NXSCF)

USD 0.07

(0.0%)

Market Cap (In USD)

20.45 Million

Revenue (In USD)

22.17 Million

Net Income (In USD)

-16.27 Million

Avg. Volume

625.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.041-0.268
PE
-
EPS
-
Beta Value
1.512
ISIN
AU0000041329
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Harry Thomas Hall
Employee Count
-
Website
https://www.nextscience.com
Ipo Date
2021-01-08
Details
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for surgical infection management; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site infections. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia.